Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02447276 | Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip | PHASE2 | COMPLETED | 421 | — | — | May 1, 2015 | Nov 1, 2016 | Mar 27, 2017 | 72 | United States |
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Group A will receive REGN475 dosing regimen 1 |
| Group B | EXPERIMENTAL | Group B will receive REGN475 dosing regimen 2 |
| Group C | EXPERIMENTAL | Group C will receive REGN475 dosing regimen 3 |
| Group D | EXPERIMENTAL | Group D will receive REGN475 dosing regimen 4 |
| Group E | EXPERIMENTAL | Group E will receive matching placebo |
| Name | Type | Description |
|---|---|---|
| REGN475 | DRUG | - |
| Placebo | DRUG | - |
Key Inclusion Criteria: 1. Body mass index ≤39 2. Clinical diagnosis of OA of the knee or hip 3. History of inadequate pain relief or intolerance to analgesics used for OA 4. Moderate to severe pain in the index joint 5. History of regular use of analgesic medications for OA pain 6. Willing to disc...